Quantitative Assessment of the Impact of Fluorine Substitution on P-Glycoprotein (P-gp) Mediated Efflux, Permeability, Lipophilicity, and Metabolic Stability

Journal of Medicinal Chemistry

Volumn 59, Issue 11, 2016, Pages 5284-5296

  Pettersson, Martin ^a   Hou, Xinjun ^a   Kuhn, Max ^a   Wager, Travis T ^a   Kauffman, Gregory W ^a   Verhoest, Patrick R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; DIPOLE; DRUG DESIGN; LIPOPHILICITY; METABOLIC STABILITY; MOLECULAR RECOGNITION; MOLECULAR SIZE; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PROTEIN CONFORMATION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PERMEABILITY;

FLUORINE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; P-GLYCOPROTEIN; PERMEABILITY;

EID: 84974627239     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00027     Document Type: Article

References (53)

1. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; DeCrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 2008, 18, 4872-4875 10.1016/j.bmcl.2008.07.071
2. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 10.1038/nrd2445
3. Leeson, P. D.; Young, R. J. Molecular property design: Does everyone get it? ACS Med. Chem. Lett. 2015, 6, 722-725 10.1021/acsmedchemlett.5b00157
4. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 10.1016/S0169-409X(96)00423-1
5. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 10.1016/S1359-6446(04)03069-7
6. 2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis Bioorg. Med. Chem. Lett. 2009, 19, 4406-4409 10.1016/j.bmcl.2009.05.062
7. Reynolds, C. H.; Tounge, B. A.; Bembenek, S. D. Ligand binding efficiency: trends, physical basis, and implications J. Med. Chem. 2008, 51, 2432-2438 10.1021/jm701255b
8. Stepan, A. F.; Kauffman, G. W.; Keefer, C. E.; Verhoest, P. R.; Edwards, M. Evaluating the differences in cycloalkyl ether metabolism using the design parameter «lipophilic metabolism efficiency» (LipMetE) and a matched molecular pairs analysis J. Med. Chem. 2013, 56, 6985-6990 10.1021/jm4008642
9. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449 10.1021/cn100008c
10. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834 10.1021/jm701122q
11. Johnson, T. W.; Dress, K. R.; Edwards, M. Using the Golden Triangle to optimize clearance and oral absorption Bioorg. Med. Chem. Lett. 2009, 19, 5560-5564 10.1016/j.bmcl.2009.08.045
12. Rosenquist, Å Samuelsson, B.; Johansson, P.-O.; Cummings, M. D.; Lenz, O.; Raboisson, P.; Simmen, K.; Vendeville, S.; de Kock, H.; Nilsson, M.; Horvath, A.; Kalmeijer, R.; de la Rosa, G.; Beumont-Mauviel, M. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor J. Med. Chem. 2014, 57, 1673-1693 10.1021/jm401507s
13. Ghosh, A. K.; Osswald, H. L.; Prato, G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS J. Med. Chem. 2016, DOI: 10.1021/acs.jmedchem.5b01697.
14. De Strooper, B.; Vassar, R.; Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer's disease Nat. Rev. Neurol. 2010, 6, 99-107 10.1038/nrneurol.2009.218
15. Pettersson, M.; Stepan, A. F.; Kauffman, G. W.; Johnson, D. S. Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012 Expert Opin. Ther. Pat. 2013, 23, 1349-1366 10.1517/13543776.2013.821465
16. Oehlrich, D.; Berthelot, D. J.-C.; Gijsen, H. J. M. γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs J. Med. Chem. 2011, 54, 669-698 10.1021/jm101168r
17. Pettersson, M.; Johnson, D. S.; Subramanyam, C.; Bales, K. R.; am Ende, C. W.; Fish, B. A.; Green, M. E.; Kauffman, G. W.; Mullins, P. B.; Navaratnam, T.; Sakya, S. M.; Stiff, C. M.; Tran, T. P.; Xie, L.; Zhang, L.; Pustilnik, L. R.; Vetelino, B. C.; Wood, K. M.; Pozdnyakov, N.; Verhoest, P. R.; O'Donnell, C. J. Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators J. Med. Chem. 2014, 57, 1046-1062 10.1021/jm401782h
18. Pettersson, M.; Johnson, D. S.; Humphrey, J. M.; Am Ende, C. W.; Evrard, E.; Efremov, I.; Kauffman, G. W.; Stepan, A. F.; Stiff, C. M.; Xie, L.; Bales, K. R.; Hajos-Korcsok, E.; Murrey, H. E.; Pustilnik, L. R.; Steyn, S. J.; Wood, K. M.; Verhoest, P. R. Discovery of indole-derived pyridopyrazine-1,6-dione γ-secretase modulators that target presenilin Bioorg. Med. Chem. Lett. 2015, 25, 908-913 10.1016/j.bmcl.2014.12.059
19. Pettersson, M.; Johnson, D. S.; Humphrey, J. M.; Butler, T. W.; Am Ende, C. W.; Fish, B. A.; Green, M. E.; Kauffman, G. W.; Mullins, P. B.; O'Donnell, C. J.; Stepan, A. F.; Stiff, C. M.; Subramanyam, C.; Tran, T. P.; Vetelino, B. C.; Yang, E.; Xie, L.; Bales, K. R.; Pustilnik, L. R.; Steyn, S. J.; Wood, K. M.; Verhoest, P. R. Design of pyridopyrazine-1,6-dione γ-secretase modulators that align potency, MDR efflux ratio, and metabolic stability ACS Med. Chem. Lett. 2015, 6, 596-601 10.1021/acsmedchemlett.5b00070
20. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 2010, 1, 420-434 10.1021/cn100007x
21. Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab. Dispos. 2008, 36, 268-275 10.1124/dmd.107.017434
22. Callegari, E.; Malhotra, B.; Bungay, P. J.; Webster, R.; Fenner, K. S.; Kempshall, S.; LaPerle, J. L.; Michel, M. C.; Kay, G. G. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder Br. J. Clin. Pharmacol. 2011, 72, 235-246 10.1111/j.1365-2125.2011.03961.x
23. Gillis, E. P.; Eastman, K. J.; Hill, M. D.; Donnelly, D. J.; Meanwell, N. A. Applications of fluorine in medicinal chemistry J. Med. Chem. 2015, 58, 8315-8359 10.1021/acs.jmedchem.5b00258
24. Xing, L.; Blakemore, D. C.; Narayanan, A.; Unwalla, R.; Lovering, F.; Denny, R. A.; Zhou, H.; Bunnage, M. E. Fluorine in drug design: a case study with fluoroanisoles ChemMedChem 2015, 10, 715-726 10.1002/cmdc.201402555
25. Hagmann, W. K. The many roles for fluorine in medicinal chemistry J. Med. Chem. 2008, 51, 4359-4369 10.1021/jm800219f
26. Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry Chem. Soc. Rev. 2008, 37, 320-330 10.1039/B610213C
27. Miller, M. M.; Liu, Y.; Jiang, J.; Johnson, J. A.; Kamau, M.; Nirschl, D. S.; Wang, Y.; Harikrishnan, L.; Taylor, D. S.; Chen, A. Y. A.; Yin, X.; Seethala, R.; Peterson, T. L.; Zvyaga, T.; Zhang, J.; Huang, C. S.; Wexler, R. R.; Poss, M. A.; Lawrence, R. M.; Adam, L. P.; Salvati, M. E. Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 6503-6508 10.1016/j.bmcl.2012.08.011
28. Zhu, Y.; Olson, S. H.; Graham, D.; Patel, G.; Hermanowski-Vosatka, A.; Mundt, S.; Shah, K.; Springer, M.; Thieringer, R.; Wright, S.; Xiao, J.; Zokian, H.; Dragovic, J.; Balkovec, J. M. Phenylcyclobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I Bioorg. Med. Chem. Lett. 2008, 18, 3412-3416 10.1016/j.bmcl.2008.04.014
29. Hameed P, S.; Patil, V.; Solapure, S.; Sharma, U.; Madhavapeddi, P.; Raichurkar, A.; Chinnapattu, M.; Manjrekar, P.; Shanbhag, G.; Puttur, J.; Shinde, V.; Menasinakai, S.; Rudrapatana, S.; Achar, V.; Awasthy, D.; Nandishaiah, R.; Humnabadkar, V.; Ghosh, A.; Narayan, C.; Ramya, V. K.; Kaur, P.; Sharma, S.; Werngren, J.; Hoffner, S.; Panduga, V.; Kumar, C. N. N.; Reddy, J.; Kumar, K. N. M.; Ganguly, S.; Bharath, S.; Bheemarao, U.; Mukherjee, K.; Arora, U.; Gaonkar, S.; Coulson, M.; Waterson, D.; Sambandamurthy, V. K.; De Sousa, S. M. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against mycobacterium tuberculosis J. Med. Chem. 2014, 57, 4889-4905 10.1021/jm500432n
30. Wager, T. T.; Pettersen, B. A.; Schmidt, A. W.; Spracklin, D. K.; Mente, S.; Butler, T. W.; Howard, H.; Lettiere, D. J.; Rubitski, D. M.; Wong, D. F.; Nedza, F. M.; Nelson, F. R.; Rollema, H.; Raggon, J. W.; Aubrecht, J.; Freeman, J. K.; Marcek, J. M.; Cianfrogna, J.; Cook, K. W.; James, L. C.; Chatman, L. A.; Iredale, P. A.; Banker, M. J.; Homiski, M. L.; Munzner, J. B.; Chandrasekaran, R. Y. Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarbox amide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyc lobutanecarboxamide (PF-03654764) J. Med. Chem. 2011, 54, 7602-7620 10.1021/jm200939b
31. Brodney, M. A.; Beck, E. M.; Butler, C. R.; Barreiro, G.; Johnson, E. F.; Riddell, D.; Parris, K.; Nolan, C. E.; Fan, Y.; Atchison, K.; Gonzales, C.; Robshaw, A. E.; Doran, S. D.; Bundesmann, M. W.; Buzon, L.; Dutra, J.; Henegar, K.; LaChapelle, E.; Hou, X.; Rogers, B. N.; Pandit, J.; Lira, R.; Martinez-Alsina, L.; Mikochik, P.; Murray, J. C.; Ogilvie, K.; Price, L.; Sakya, S. M.; Yu, A.; Zhang, Y.; O'Neill, B. T. Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors J. Med. Chem. 2015, 58, 3223-3252 10.1021/acs.jmedchem.5b00191
32. Bonomo, S.; Tosco, P.; Giorgis, M.; Lolli, M.; Fruttero, R. The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors J. Mol. Model. 2013, 19, 1099-1107 10.1007/s00894-012-1643-5
33. Tanaka, H.; Shishido, Y. Synthesis of aromatic compounds containing a 1,1-dialkyl-2-trifluoromethyl group, a bioisostere of the tert-alkyl moiety Bioorg. Med. Chem. Lett. 2007, 17, 6079-6085 10.1016/j.bmcl.2007.09.053
34. Barnes-Seeman, D.; Jain, M.; Bell, L.; Ferreira, S.; Cohen, S.; Chen, X. H.; Amin, J.; Snodgrass, B.; Hatsis, P. Metabolically stable tert-butyl replacement ACS Med. Chem. Lett. 2013, 4, 514-516 10.1021/ml400045j
35. Lobell, M.; Hendrix, M.; Hinzen, B.; Keldenich, J.; Meier, H.; Schmeck, C.; Schohe-Loop, R.; Wunberg, T.; Hillisch, A. In silico ADMET traffic lights as a tool for the prioritization of HTS hits ChemMedChem 2006, 1, 1229-1236 10.1002/cmdc.200600168
36. Hastie, T.; Tibshirani, R.; Friedman, J. The Elements of Statistical Learning; Springer: New York, 2009.
37. Kuhn, M.; Johnson, K. Applied Predictive Modeling; Springer: New York, 2013.
38. Morgenthaler, M.; Schweizer, E.; Hoffmann-Röder, A.; Benini, F.; Martin, R. E.; Jaeschke, G.; Wagner, B.; Fischer, H.; Bendels, S.; Zimmerli, D.; Schneider, J.; Diederich, F.; Kansy, M.; Müller, K. Predicting and tuning physicochemical properties in lead optimization: amine basicities ChemMedChem 2007, 2, 1100-1115 10.1002/cmdc.200700059
39. Smart, B. E. Fluorine substituent effects (on bioactivity) J. Fluorine Chem. 2001, 109, 3-11 10.1016/S0022-1139(01)00375-X
40. Huchet, Q. A.; Kuhn, B.; Wagner, B.; Kratochwil, N. A.; Fischer, H.; Kansy, M.; Zimmerli, D.; Carreira, E. M.; Muller, K. Fluorination patterning: A study of structural motifs that impact physicochemical properties of relevance to drug discovery J. Med. Chem. 2015, 58, 9041-9060 10.1021/acs.jmedchem.5b01455
41. Shake flask logD. Assay method adapted from published protocol: Hay, T.; Jones, R.; Beaumont, K.; Kemp, M. Modulation of the partition coefficient between octanol and buffer at pH 7.4 and pKa to achieve the optimum balance of blood clearance and volume of distribution for a series of tetrahydropyran histamine type 3 receptor antagonists Drug Metab. Dispos. 2009, 37, 1864-1870 10.1124/dmd.109.027888
42. Bondi, A. van der Waals volumes and radii J. Phys. Chem. 1964, 68, 441-445 10.1021/j100785a001
43. Leo, A.; Hansch, C.; Jow, P. Y. C. Dependence of hydrophobicity of apolar molecules on their molecular volume J. Med. Chem. 1976, 19, 611-615 10.1021/jm00227a007
44. Abraham, M. H.; McGowan, J. C. The use of characteristic volumes to measure cavity terms in reversed phase liquid chromatography Chromatographia 1987, 23, 243-246 10.1007/BF02311772
45. Galvez, J. Prediction of molecular volume and surface of alkanes by molecular topology J. Chem. Inf. Comput. Sci. 2003, 43, 1231-1239 10.1021/ci034036x
46. Zhao, Y. H.; Abraham, M. H.; Zissimos, A. M. Determination of McGowan volumes for ions and correlation with van der Waals volumes J. Chem. Inf. Comput. Sci. 2003, 43, 1848-1854 10.1021/ci0341114
47. Pipeline Pilot, version 9; Accelrys, Inc.: San Diego, CA, 2013.
48. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 10.1093/nar/28.1.235
49. Corina, version 3.6; Molecular Networks: Erlangen, Germany, 2014.
50. OMEGA, version 2.5.1.4; OpenEye Scientific Software: Santa Fe, NM, U.S.
51. Keefer, C. E.; Chang, G.; Kauffman, G. W. Extraction of tacit knowledge from large ADME data sets via pairwise analysis Bioorg. Med. Chem. 2011, 19, 3739-3749 10.1016/j.bmc.2011.05.003
52. Assay method adapted from published protocols: Riley, R. J.; McGinnity, D. F.; Austin, R. P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes Drug. Metab. Dispos. 2005, 33, 1304-1311 10.1124/dmd.105.004259
53. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes Drug. Metab. Dispos. 1999, 27, 1350-1359